BioCentury
ARTICLE | Clinical News

IV solithromycin: Completed Phase III enrollment

July 20, 2015 7:00 AM UTC

Cempra completed enrollment of 863 patients in the double-blind, international Phase III Solitaire-IV trial comparing once-daily IV solithromycin for 7 days vs. IV moxifloxacin for 7 days. Patients will receive an 800 mg solithromycin loading dose and 400 mg thereafter. Patients can switch to oral dosing of their assigned drug based on a decision by their physician. ...